**Pivot Pharma Engages Harris Bricken LLP for California Cannabis Compliance Services**

VANCOUVER, BC (April 25, 2019) – [Pivot Pharmaceuticals Inc](http://www.pivotpharma.com/). (CSE: [PVOT](http://thecse.com/en/listings/life-sciences/pivot-pharmaceuticals-inc)) (OTCQB: [PVOTF](https://www.otcmarkets.com/stock/PVOTF/quote)) (“Pivot” or the “Company”) is pleased to announce that it has retained the law firm, Harris Bricken LLP, to provide the Company with legal planning, regulatory support, corporate guidance, and compliance strategies for the U.S. cannabis market. Harris Bricken is an international law firm with lawyers in Los Angeles, Portland, San Francisco, Seattle, Barcelona, and Beijing. Harris Bricken’s cannabis attorneys are recognized national leaders at the forefront of the cannabis industry.

Pivot’s wholly-owned U.S. subsidiary, Pivot Naturals, LLC (“Pivot Naturals”), based in Costa Mesa, California, was granted a Temporary Manufacturing Type N: Infusion License by the California Department of Public Health (“CDPH”) in November 2018 and a Temporary Transport-Only Distribution License from the Bureau of Cannabis Control (“BCC”) in December 2018. Harris Bricken will assist Pivot through the final process required to secure Annual Manufacturing and Transport-Only Distribution Licenses for Pivot Naturals. Pivot’s Board of Directors continues to submit all required information to the BCC and the CDPH. In addition, the Company’s former Chairman, Mr. Ahmad Doroudian, will be also be added to the Licenses due to his aggregate share ownership interest exceeding 5%.

Patrick Frankham, Pivot’s CEO stated, “We welcome Harris Bricken to the Pivot team to help navigate the cannabis regulations in California. As we prepare to commercialize our products in the U.S, Harris Bricken’s advice and guidance will be invaluable to our Board of Directors.”

**About Pivot Pharmaceuticals Inc.**

Pivot Pharmaceuticals Inc. is a science-based consumer packaged goods cannabis company engaged in the development and commercialization of health and wellness products using innovative, patent-protected drug delivery technologies. Upon receipt of a Standard Processor license (pending) from Health Canada, Pivot’s premium, bioavailable, stable and effective products will be manufactured at its 50,000-sq. ft. cGMP facility located in Montreal, Quebec. Pivot’s wholly-owned U.S. subsidiary, Pivot Naturals, LLC, based in Costa Mesa, California, was granted a Temporary Manufacturing Type N: Infusion License by the California Department of Public Health in November 2018 and a Temporary Transport-Only Distribution License from the Bureau of Cannabis Control in December 2018. Pivot’s product line includes infused beverages, vegan capsules, dissolvable tablets, topical creams and gels, intimate lubricants, roll-on pain relievers, stick packs, and bulk powder for the edibles market. For more information please visit [pivotpharma.com](http://www.pivotpharma.com/)

**Cautionary Note Regarding Forward-Looking Statements:**

*Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as anticipate, believe, estimate, expect, intend, and similar expressions, as they relate to Pivot Pharmaceuticals Inc., Pivot Green Stream Health Solutions Inc., Pivot Naturals, LLC., or its management, identify forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, such as the failure to meet the conditions imposed by the CSE or other securities regulators, the level of business and consumer spending, the amount of sales of Pivot's products, statements with respect to internal expectations, the competitive environment within the industry, the ability of Pivot to continue to expand its operations, the level of costs incurred in connection with Pivot's expansion efforts, economic conditions in the industry, and the financial strength of Pivot's customers and suppliers. Pivot does not undertake any obligation to update such forward-looking statements. Investors are also directed to consider all other risks and uncertainties.*

**Contact:**

Pivot Pharmaceuticals Inc.

Patrick Frankham, PhD, MBA

Chief Executive Officer

Email: [Info@PivotPharma.com](mailto:Info@PivotPharma.com)

Virtus Advisory Group

Shareholder Inquiries

Email: [Pivot@virtusadvisory.com](mailto:pivot@virtusadvisory.com?subject=Pivot%20Pharma)

Phone: 416-644-5081